Cell and gene therapy is rapidly moving from early access into mainstream medicine. With 13 CAR T therapies approved around the world and thousands more in development, adoption is accelerating across new indications, including autoimmune disease, and expanding beyond major academic centers into outpatient and remote settings. According to Dr. Rohin Iyer, this momentum is redefining expectations for how quickly and reliably these therapies must reach patients.
As therapies scale, the pressure points are clear: manufacturability, affordability and vein‑to‑vein speed. Shortened manufacturing timelines—from weeks to days—raise the bar for coordination across collection sites, logistics partners and manufacturing facilities. With no room for error, every handoff matters, and every delay has direct implications for patient outcomes.
To meet these demands, the industry is embracing pharmaceutical‑grade logistics standards, real‑time telemetry and AI‑driven analytics. Continuous monitoring, proactive risk detection and resilient air and ground networks are no longer differentiators—they are prerequisites as CGT therapies move toward broader clinical adoption.
The editorial staff had no role in this post's creation.